{"component": "definition", "props": {"groups": [{"samples": [{"hash": "cBlQ6dTV8Mr", "uri": "/contracts/cBlQ6dTV8Mr#licensed-compounds", "label": "Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "mNHm0OY40j", "uri": "/contracts/mNHm0OY40j#licensed-compounds", "label": "Collaboration Agreement (Discovery Partners International Inc)", "score": 21.0, "published": true}, {"hash": "i3bRX4mtKZe", "uri": "/contracts/i3bRX4mtKZe#licensed-compounds", "label": "Collaboration Agreement (Infinity Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet": "means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a \u201cLicensed Compound\u201d).", "size": 6, "snippet_links": [{"key": "research-program", "type": "clause", "offset": [11, 27]}, {"key": "active-compounds", "type": "clause", "offset": [28, 44]}, {"key": "the-foregoing", "type": "clause", "offset": [331, 344]}, {"key": "licensed-compound", "type": "definition", "offset": [349, 366]}], "hash": "c4d28c485812e816983f87e5c8418347", "id": 1}, {"samples": [{"hash": "UZK1t2cl9T", "uri": "/contracts/UZK1t2cl9T#licensed-compounds", "label": "License Agreement", "score": 35.3694419861, "published": true}, {"hash": "kE8pjttLRi6", "uri": "/contracts/kE8pjttLRi6#licensed-compounds", "label": "License Agreement", "score": 28.6865272522, "published": true}, {"hash": "ci96oYIbTyR", "uri": "/contracts/ci96oYIbTyR#licensed-compounds", "label": "License Agreement", "score": 28.5031242371, "published": true}], "snippet": "means the antiretroviral compounds known as lopinavir and ritonavir, individually or in combination, manufactured or sold for the sole purpose of use in Licensed Product solely for Exploitation in the Field in the Territory.", "size": 5, "snippet_links": [{"key": "in-combination", "type": "definition", "offset": [85, 99]}, {"key": "purpose-of-use", "type": "definition", "offset": [135, 149]}, {"key": "licensed-product", "type": "clause", "offset": [153, 169]}, {"key": "in-the-field", "type": "clause", "offset": [194, 206]}, {"key": "in-the-territory", "type": "clause", "offset": [207, 223]}], "hash": "8c440d371863270d27c2fdfd598b12dd", "id": 2}, {"samples": [{"hash": "9m7ph8xgnbN", "uri": "/contracts/9m7ph8xgnbN#licensed-compounds", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 32.1457901001, "published": true}, {"hash": "1dS7TxoQ6Hg", "uri": "/contracts/1dS7TxoQ6Hg#licensed-compounds", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "ew6NIZCekN6", "uri": "/contracts/ew6NIZCekN6#licensed-compounds", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 26.201915741, "published": true}], "snippet": "means any EZH2 Compound(s) that is:\n(a) synthesized or identified by either Party (or by any of its respective Affiliates or any Third Party working with or on behalf of such Party or any of its respective Affiliates) or jointly by or on behalf of the Parties in the conduct of the Collaboration or in the exercise of such Party\u2019s licenses under this Agreement from and after the Prior Agreement Effective Date, excluding Compounds Controlled by either Party and first identified as EZH2 Compounds after the expiration of the Target Exclusivity Period; or\n(b) otherwise Controlled by EPIZYME as of the Prior Agreement Effective Date or at any time thereafter prior to the expiration of the Target Exclusivity Period.", "size": 5, "snippet_links": [{"key": "by-either-party", "type": "clause", "offset": [66, 81]}, {"key": "respective-affiliates", "type": "definition", "offset": [100, 121]}, {"key": "third-party", "type": "definition", "offset": [129, 140]}, {"key": "working-with", "type": "definition", "offset": [141, 153]}, {"key": "such-party", "type": "clause", "offset": [170, 180]}, {"key": "of-the-parties", "type": "clause", "offset": [245, 259]}, {"key": "conduct-of-the-collaboration", "type": "clause", "offset": [267, 295]}, {"key": "exercise-of", "type": "clause", "offset": [306, 317]}, {"key": "this-agreement", "type": "clause", "offset": [346, 360]}, {"key": "prior-agreement-effective-date", "type": "definition", "offset": [380, 410]}, {"key": "target-exclusivity-period", "type": "definition", "offset": [526, 551]}, {"key": "at-any-time", "type": "clause", "offset": [636, 647]}, {"key": "prior-to-the", "type": "clause", "offset": [659, 671]}], "hash": "e1a054699ffba7ee01317a64e2cbbcd8", "id": 3}, {"samples": [{"hash": "izkNgBnAuoO", "uri": "/contracts/izkNgBnAuoO#licensed-compounds", "label": "License Agreement (Versicor Inc /Ca)", "score": 18.0, "published": true}, {"hash": "8jhvOPeBO2S", "uri": "/contracts/8jhvOPeBO2S#licensed-compounds", "label": "License Agreement (Versicor Inc /Ca)", "score": 18.0, "published": true}], "snippet": "means the Compound or any other compound claimed in the Licensed Patents.", "size": 5, "snippet_links": [{"key": "other-compound", "type": "definition", "offset": [26, 40]}, {"key": "licensed-patents", "type": "definition", "offset": [56, 72]}], "hash": "b20ceabb6986917cef40c57ddf0e78c5", "id": 4}, {"samples": [{"hash": "knxU6sgGxaf", "uri": "/contracts/knxU6sgGxaf#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 33.2245025635, "published": true}, {"hash": "4gJRxMjC6ka", "uri": "/contracts/4gJRxMjC6ka#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 32.4798088074, "published": true}, {"hash": "f5QS7bHrhFY", "uri": "/contracts/f5QS7bHrhFY#licensed-compounds", "label": "Exclusive License Agreement (Erasca, Inc.)", "score": 32.4360046387, "published": true}], "snippet": "means (i) JCN068, (ii) any Back-up Compounds, and (iii) all prodrugs, metabolites, stereoisomers, diastereomers, enantiomers, tautomers, solvates, hydrate forms, homologs, salt forms, labeled forms (e.g., deuterated, 13C enriched, etc.), esters, crystalline forms (e.g., polymorphs), semi-crystalline forms, and amorphous forms, of any of the foregoing compounds.", "size": 4, "snippet_links": [{"key": "the-foregoing", "type": "clause", "offset": [339, 352]}], "hash": "b3f0b895e6931677cb8b6b24c3bfba46", "id": 5}, {"samples": [{"hash": "da9aBQllr7S", "uri": "/contracts/da9aBQllr7S#licensed-compounds", "label": "License, Development, and Commercialization Agreement (Prothena Corp PLC)", "score": 25.42710495, "published": true}, {"hash": "jWF7rQ6VTwU", "uri": "/contracts/jWF7rQ6VTwU#licensed-compounds", "label": "License, Development, and Commercialization Agreement (Prothena Corp PLC)", "score": 25.1779594421, "published": true}, {"hash": "30Bxs4KpB8O", "uri": "https://s29.q4cdn.com/936209790/files/doc_financials/2013/q4/0001559053-14-000007.pdf", "label": "s29.q4cdn.com", "score": 9.9637231827, "published": false}], "snippet": "means (a) the Lead Compound, (b) any Licensed Prothena Compounds, (c) any Licensed Roche Compounds, and (d) any Research Collaboration Compounds. [*]", "size": 4, "snippet_links": [{"key": "lead-compound", "type": "definition", "offset": [14, 27]}, {"key": "collaboration-compounds", "type": "definition", "offset": [121, 144]}], "hash": "eda5353f591f28a9f18ad14149d8bcb4", "id": 6}, {"samples": [{"hash": "7NCXiDPl4vl", "uri": "/contracts/7NCXiDPl4vl#licensed-compounds", "label": "License Agreement (Panacos Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "bz0Hyu1qUcE", "uri": "https://sec.report/Document/0001193125-09-010492/0001193125-09-010492.txt", "label": "sec.report", "score": 10.1704311371, "published": false}], "snippet": "means any individual compounds whose manufacture, use, sale, offer for sale or importation is covered by any University Technology or Niigata Technology or by one or more Valid Claims of the Patents.", "size": 4, "snippet_links": [{"key": "offer-for-sale", "type": "clause", "offset": [61, 75]}, {"key": "covered-by", "type": "definition", "offset": [94, 104]}, {"key": "university-technology", "type": "definition", "offset": [109, 130]}, {"key": "claims-of", "type": "clause", "offset": [177, 186]}, {"key": "the-patents", "type": "clause", "offset": [187, 198]}], "hash": "1e85df4d2ece039adaae98c330e1b591", "id": 7}, {"samples": [{"hash": "7KWrwN4x1UQ", "uri": "/contracts/7KWrwN4x1UQ#licensed-compounds", "label": "License Agreement (Metsera, Inc.)", "score": 36.0253257751, "published": true}, {"hash": "40vIgs5C0OA", "uri": "/contracts/40vIgs5C0OA#licensed-compounds", "label": "License Agreement (Metsera, Inc.)", "score": 35.9459266663, "published": true}], "snippet": "means [***].", "size": 4, "snippet_links": [], "hash": "42145ccc68badf480a8ed917c57dd5fc", "id": 8}, {"samples": [{"hash": "jDTZ2wOfu1C", "uri": "/contracts/jDTZ2wOfu1C#licensed-compounds", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.5242977142, "published": true}, {"hash": "elvknFyTYBd", "uri": "/contracts/elvknFyTYBd#licensed-compounds", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.3709793091, "published": true}, {"hash": "gizMheTuIY8", "uri": "/contracts/gizMheTuIY8#licensed-compounds", "label": "License Agreement (Checkpoint Therapeutics, Inc.)", "score": 27.2258720398, "published": true}], "snippet": "means (a) the compound known as CEP-9722, as further described on Schedule 3, which compound is an oral low nM PARP inhibitor, and (b) the compound known as CEP-8983, as further described on Schedule 3.", "size": 3, "snippet_links": [{"key": "schedule-3", "type": "clause", "offset": [66, 76]}], "hash": "28e298ae068bc7b685270ba5ac6099c1", "id": 9}, {"samples": [{"hash": "fLVxyQOW7CM", "uri": "/contracts/fLVxyQOW7CM#licensed-compounds", "label": "License Agreement (Ardelyx, Inc.)", "score": 37.1341552734, "published": true}, {"hash": "28f7XGzakK", "uri": "/contracts/28f7XGzakK#licensed-compounds", "label": "License Agreement (Ardelyx, Inc.)", "score": 29.1971244812, "published": true}, {"hash": "jQcMiOQ7rGK", "uri": "https://ir.ardelyx.com/static-files/994f7693-fb6f-4bf6-befa-aaf3869c0c31", "label": "ir.ardelyx.com", "score": 11.2943191528, "published": false}], "snippet": "means the Lead Licensed Compound and any and all Backup Licensed Compounds.", "size": 3, "snippet_links": [{"key": "lead-licensed-compound", "type": "definition", "offset": [10, 32]}, {"key": "backup-licensed-compounds", "type": "definition", "offset": [49, 74]}], "hash": "be5995d3491e5ef06938819e218698b4", "id": 10}], "next_curs": "Cl8SWWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjsLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIbbGljZW5zZWQtY29tcG91bmRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Licensed Compounds", "snippet": "means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a \u201cLicensed Compound\u201d).", "size": 218, "id": "licensed-compounds", "examples": ["Upon GSK\u2019s reasonable request, CAMP4 shall, and shall cause its Affiliates to, provide to GSK and its Affiliates any documents, data or other materials in the Control of CAMP4 or any of its Affiliates as may be necessary or reasonably useful for GSK or any of its Affiliates or Sublicensees to obtain Regulatory Approvals for any <strong>Licensed Compounds</strong> or Licensed Products in the Territory.", "As between the Parties, GSK shall solely and exclusively own and have the sole and exclusive right to prepare, maintain and develop any and all Regulatory Documents and Regulatory Approvals for any <strong>Licensed Compounds</strong> and Licensed Products in the Territory, including all INDs and \u2587\u2587\u2587\u2587.", "Except for [***] under, and in accordance with, the Research Plans, as between the Parties, GSK shall have the sole and exclusive right, and sole and exclusive responsibility and decision-making authority, at its cost, to Manufacture and supply any and all <strong>Licensed Compounds</strong> and Licensed Products in the Field in and for the Territory.", "During the Term, GSK (or one of its Affiliates, licensees or Sublicensees) shall be solely responsible, and act as the sole point of contact, for communications with Regulatory Authorities in connection with the Exploitation of any <strong>Licensed Compounds</strong> or Licensed Products in the Territory."], "related": [["licensed-compound", "Licensed Compound", "Licensed Compound"], ["licensed-antibody", "Licensed Antibody", "Licensed Antibody"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["collaboration-product", "Collaboration Product", "Collaboration Product"], ["licensed-products", "Licensed Products", "Licensed Products"]], "related_snippets": [], "updated": "2026-03-07T04:27:53+00:00"}, "json": true, "cursor": ""}}